In the Aβ-positive group, the tau PET result led to a significant change in diagnoses in 55 participants (9.9%) (38 changed from pre-PET AD to a post-PET non-AD diagnosis and 17 from a pre-PET non-AD to a post-PET AD diagnosis; McNemar test, P = .01). Here, MAPT is linked to Alzheimer disease.